secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2023-11-30T23:59:59+00:00
Accession:  0001326190-23-000050
Event type: other_material
Sentiment:  positive
Materiality: 0.82
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune reports Phase 2 obesity trial: 15.6% mean weight loss with pemvidutide 2.4 mg at Week 48
--------------------------------------------------------------------------------

- Mean weight loss of 15.6% on 2.4 mg dose vs 2.2% placebo; near-linear trajectory at end of treatment.
- Over 30% of subjects achieved ≥20% weight loss on 2.4 mg; 83.9% achieved ≥5% weight loss.
- Robust reductions in serum lipids and blood pressure without cardiac safety imbalances; zero MACE events.
- Discontinuation rates higher at higher doses: 19.6% (2.4 mg) vs 6.2% placebo; most due to GI AEs in first 16 weeks.
- Only one drug-related SAE (vomiting at 2.4 mg); nausea/vomiting predominantly mild to moderate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619023000050/0001326190-23-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619023000050/alt-20231130x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-23-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer